Charles River Laboratories completed the acquisition of Cognate BioServices for $875m.

Charles River Laboratories, an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries, completed its acquisition of Cognate BioServices, a biologics CDMO, for $875m. "We are pleased to welcome the exceptional team at Cognate to the Charles River family, and look forward to working together to provide clients with an integrated solution to help accelerate their cell and gene therapy programs from discovery and non-clinical development through commercialization. We believe Cognate will meaningfully enhance our long-term revenue and earnings growth potential because of the synergistic fit with Charles River, the market growth potential, and the emerging role of advanced drug modalities as treatments for oncology, rare diseases, and other therapeutic areas," James C. Foster, Charles River Laboratories Chairman, President and CEO.